AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 195 filers reported holding AXSOME THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,706,854 | -1.0% | 95,963 | +1.8% | 0.02% | 0.0% |
| Q2 2023 | $6,774,817 | +24.0% | 94,278 | +6.5% | 0.02% | +17.6% |
| Q1 2023 | $5,461,456 | -20.2% | 88,545 | -0.2% | 0.02% | -26.1% |
| Q4 2022 | $6,844,439 | +15.9% | 88,739 | -33.6% | 0.02% | +9.5% |
| Q3 2022 | $5,903,000 | +25.7% | 133,705 | +3.9% | 0.02% | +23.5% |
| Q2 2022 | $4,695,000 | -11.8% | 128,677 | -0.0% | 0.02% | +13.3% |
| Q1 2022 | $5,323,000 | +17.0% | 128,692 | +6.9% | 0.02% | +50.0% |
| Q4 2021 | $4,550,000 | +86.6% | 120,440 | +62.8% | 0.01% | +66.7% |
| Q3 2021 | $2,438,000 | -50.9% | 73,969 | +0.5% | 0.01% | -53.8% |
| Q2 2021 | $4,965,000 | +24.1% | 73,598 | +4.2% | 0.01% | +18.2% |
| Q1 2021 | $4,001,000 | -31.9% | 70,664 | -2.0% | 0.01% | -31.2% |
| Q4 2020 | $5,875,000 | +14.7% | 72,107 | +0.3% | 0.02% | -11.1% |
| Q3 2020 | $5,124,000 | +35.4% | 71,910 | +56.3% | 0.02% | +20.0% |
| Q2 2020 | $3,785,000 | +81.1% | 46,005 | +29.5% | 0.02% | +25.0% |
| Q1 2020 | $2,090,000 | – | 35,521 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
| MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
| Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
| WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
| Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
| RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
| MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
| Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
| Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |